1-3 of 3
Douglas O Clary, PhD
Close
Sort by
Journal Articles

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

Dana T. Aftab, PhD, Mari I. Suominen, Douglas O. Clary, PhD, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen
Journal: Blood
Blood (2014) 124 (21): 3442.
https://doi.org/10.1182/blood.V124.21.3442.3442
Published: 2014
Journal Articles

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Neil P. Shah, MD, PhD, Patrycja Olszynski, Lubomir Sokol, MD, PhD, Srdan Verstovsek, Ronald Hoffman, MD, Alan F. List, MD, Jorge Cortes, MD, Hagop M Kantarjian, D. Gary Gilliland, Douglas O Clary, PhD, Lynne A. Bui, MD, Martha Wadleigh, MD
Journal: Blood
Blood (2008) 112 (11): 98.
https://doi.org/10.1182/blood.V112.11.98.98
Published: 2008
Journal Articles

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph + + Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Jorge Cortes, MD, Ronald Paquette, MD, Moshe Talpaz, Javier Pinilla, MD, PhD, Ekatherine Asatiani, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Corynn Kasap, BS, Lynne A. Bui, MD, Douglas O. Clary, PhD, Neil Shah, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3232.
https://doi.org/10.1182/blood.V112.11.3232.3232
Published: 2008